137 related articles for article (PubMed ID: 12392704)
1. Secretory leukocyte protease inhibitor: inhibition of human immunodeficiency virus-1 infection of monocytic THP-1 cells by a newly cloned protein.
Shine NR; Wang SC; Konopka K; Burks EA; Düzgüneş N; Whitman CP
Bioorg Chem; 2002 Aug; 30(4):249-63. PubMed ID: 12392704
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription.
McNeely TB; Shugars DC; Rosendahl M; Tucker C; Eisenberg SP; Wahl SM
Blood; 1997 Aug; 90(3):1141-9. PubMed ID: 9242546
[TBL] [Abstract][Full Text] [Related]
3. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.
McNeely TB; Dealy M; Dripps DJ; Orenstein JM; Eisenberg SP; Wahl SM
J Clin Invest; 1995 Jul; 96(1):456-64. PubMed ID: 7615818
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor.
Turpin JA; Schaeffer CA; Bu M; Graham L; Buckheit RW; Clanton D; Rice WG
Antiviral Res; 1996 Mar; 29(2-3):269-77. PubMed ID: 8739605
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism.
Skott P; Lucht E; Ehnlund M; Björling E
Oral Dis; 2002 May; 8(3):160-7. PubMed ID: 12108760
[TBL] [Abstract][Full Text] [Related]
6. Secretory leukocyte protease inhibitor (SLPI): oxidation of SLPI does not explain its variable anti-HIV activity.
Konopka K; Shine N; Pretzer E; Düzgüneş N
J Dent Res; 1999 Dec; 78(12):1773-6. PubMed ID: 10598905
[TBL] [Abstract][Full Text] [Related]
7. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I.
Wahl SM; McNeely TB; Janoff EN; Shugars D; Worley P; Tucker C; Orenstein JM
Oral Dis; 1997 May; 3 Suppl 1():S64-9. PubMed ID: 9456660
[TBL] [Abstract][Full Text] [Related]
8. Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I.
Shugars DC; Sauls DL; Weinberg JB
Oral Dis; 1997 May; 3 Suppl 1():S70-2. PubMed ID: 9456661
[TBL] [Abstract][Full Text] [Related]
9. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity.
Jana NK; Gray LR; Shugars DC
J Virol; 2005 May; 79(10):6432-40. PubMed ID: 15858026
[TBL] [Abstract][Full Text] [Related]
10. Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers.
Hocini H; Becquart P; Bouhlal H; Adle-Biassette H; Kazatchkine MD; Bélec L
Clin Diagn Lab Immunol; 2000 May; 7(3):515-8. PubMed ID: 10799472
[TBL] [Abstract][Full Text] [Related]
11. Constitutive and regulated secretion of secretory leukocyte proteinase inhibitor by human intestinal epithelial cells.
Si-Tahar M; Merlin D; Sitaraman S; Madara JL
Gastroenterology; 2000 Jun; 118(6):1061-71. PubMed ID: 10833481
[TBL] [Abstract][Full Text] [Related]
12. Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues.
Wahl SM; Worley P; Jin W; McNeely TB; Eisenberg S; Fasching C; Orenstein JM; Janoff EN
Am J Pathol; 1997 Apr; 150(4):1275-84. PubMed ID: 9094984
[TBL] [Abstract][Full Text] [Related]
13. Endogenous salivary inhibitors of human immunodeficiency virus.
Shugars DC; Alexander AL; Fu K; Freel SA
Arch Oral Biol; 1999 Jun; 44(6):445-53. PubMed ID: 10401522
[TBL] [Abstract][Full Text] [Related]
14. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk.
Farquhar C; VanCott TC; Mbori-Ngacha DA; Horani L; Bosire RK; Kreiss JK; Richardson BA; John-Stewart GC
J Infect Dis; 2002 Oct; 186(8):1173-6. PubMed ID: 12355371
[TBL] [Abstract][Full Text] [Related]
15. Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients.
Baqui AA; Meiller TF; Falkler WA
Clin Diagn Lab Immunol; 1999 Nov; 6(6):808-11. PubMed ID: 10548568
[TBL] [Abstract][Full Text] [Related]
16. Differential inhibition of mast cell chymases by secretory leukocyte protease inhibitor.
Pemberton AD; Huntley JF; Miller HR
Biochim Biophys Acta; 1998 Jan; 1379(1):29-34. PubMed ID: 9468329
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel secretory leukocyte protease inhibitor-binding protein involved in membrane phospholipid movement.
Tseng CC; Tseng CP
FEBS Lett; 2000 Jun; 475(3):232-6. PubMed ID: 10869562
[TBL] [Abstract][Full Text] [Related]
18. Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor.
Draper D; Donohoe W; Mortimer L; Heine RP
J Infect Dis; 1998 Sep; 178(3):815-9. PubMed ID: 9728551
[TBL] [Abstract][Full Text] [Related]
19. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection.
Ma G; Greenwell-Wild T; Lei K; Jin W; Swisher J; Hardegen N; Wild CT; Wahl SM
J Exp Med; 2004 Nov; 200(10):1337-46. PubMed ID: 15545357
[TBL] [Abstract][Full Text] [Related]
20. Secretory leukocyte protease inhibitor is a novel inhibitor of fibroblast-mediated collagen gel contraction.
Sumi Y; Muramatsu H; Hata K; Ueda M; Muramatsu T
Exp Cell Res; 2000 Apr; 256(1):203-12. PubMed ID: 10739667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
